Drug intelligence / Profile preview

MB100

Development stage: Preclinical
Lead developer: Mainline Biosciences
Modality: Peptides

Overview

MB100 is a peptide-based drug candidate currently in preclinical development by Mainline Biosciences. It is designed to target the C-X-C chemokine receptor type 4 (CXCR4), a G protein-coupled receptor that plays a pivotal role in cell migration, hematopoiesis, and the inflammatory response. By modulating CXCR4 signaling, MB100 is being investigated for its therapeutic potential in treating various tumors and fibrotic conditions, specifically hepatic fibrosis and pulmonary fibrosis. In oncology, CXCR4 is often overexpressed and associated with tumor metastasis and survival, while in fibrosis, it is involved in the recruitment and activation of fibroblasts.

Other names: microbead 100microbead100microbead-100100 beads/L of 0.2 µm polystyrene MB

Targets

CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on MB100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB100.

Explore the full profile